Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-01-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-020-00392-1 |
| _version_ | 1819320557349371904 |
|---|---|
| author | Francesca Palandri Giuseppe Alberto Palumbo Elena Maria Elli Nicola Polverelli Giulia Benevolo Bruno Martino Elisabetta Abruzzese Mario Tiribelli Alessia Tieghi Roberto Latagliata Francesco Cavazzini Micaela Bergamaschi Gianni Binotto Monica Crugnola Alessandro Isidori Giovanni Caocci Florian Heidel Novella Pugliese Costanza Bosi Daniela Bartoletti Giuseppe Auteri Daniele Cattaneo Luigi Scaffidi Malgorzata Monica Trawinska Rossella Stella Fiorella Ciantia Fabrizio Pane Antonio Cuneo Mauro Krampera Gianpietro Semenzato Roberto Massimo Lemoli Alessandra Iurlo Nicola Vianelli Michele Cavo Massimo Breccia Massimiliano Bonifacio |
| author_facet | Francesca Palandri Giuseppe Alberto Palumbo Elena Maria Elli Nicola Polverelli Giulia Benevolo Bruno Martino Elisabetta Abruzzese Mario Tiribelli Alessia Tieghi Roberto Latagliata Francesco Cavazzini Micaela Bergamaschi Gianni Binotto Monica Crugnola Alessandro Isidori Giovanni Caocci Florian Heidel Novella Pugliese Costanza Bosi Daniela Bartoletti Giuseppe Auteri Daniele Cattaneo Luigi Scaffidi Malgorzata Monica Trawinska Rossella Stella Fiorella Ciantia Fabrizio Pane Antonio Cuneo Mauro Krampera Gianpietro Semenzato Roberto Massimo Lemoli Alessandra Iurlo Nicola Vianelli Michele Cavo Massimo Breccia Massimiliano Bonifacio |
| author_sort | Francesca Palandri |
| collection | DOAJ |
| first_indexed | 2024-12-24T11:21:28Z |
| format | Article |
| id | doaj.art-1a0e0feee4a847eb9105d5df87c25b48 |
| institution | Directory Open Access Journal |
| issn | 2044-5385 |
| language | English |
| last_indexed | 2024-12-24T11:21:28Z |
| publishDate | 2021-01-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj.art-1a0e0feee4a847eb9105d5df87c25b482022-12-21T16:58:13ZengNature Publishing GroupBlood Cancer Journal2044-53852021-01-011111410.1038/s41408-020-00392-1Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosisFrancesca Palandri0Giuseppe Alberto Palumbo1Elena Maria Elli2Nicola Polverelli3Giulia Benevolo4Bruno Martino5Elisabetta Abruzzese6Mario Tiribelli7Alessia Tieghi8Roberto Latagliata9Francesco Cavazzini10Micaela Bergamaschi11Gianni Binotto12Monica Crugnola13Alessandro Isidori14Giovanni Caocci15Florian Heidel16Novella Pugliese17Costanza Bosi18Daniela Bartoletti19Giuseppe Auteri20Daniele Cattaneo21Luigi Scaffidi22Malgorzata Monica Trawinska23Rossella Stella24Fiorella Ciantia25Fabrizio Pane26Antonio Cuneo27Mauro Krampera28Gianpietro Semenzato29Roberto Massimo Lemoli30Alessandra Iurlo31Nicola Vianelli32Michele Cavo33Massimo Breccia34Massimiliano Bonifacio35Azienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di EmatologiaDepartment of Scienze Mediche, Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia”, University of CataniaHematology Division, San Gerardo Hospital, ASST MonzaUnit of Blood Diseases and Stem Cells Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili of BresciaDivision of Hematology, Città della Salute e della Scienza HospitalDivision of Hematology, Azienda Ospedaliera ‘Bianchi Melacrino Morelli’Division of Hematology, Ospedale S. EugenioDivision of Hematology and BMT, Department of Medical Area, University of UdineDepartment of Hematology, Azienda USL - IRCCS di Reggio EmiliaDivision of Cellular Biotechnologies and Hematology, University SapienzaDivision of Hematology, University of FerraraClinic of Hematology, Department of Internal Medicine (DiMI), IRCCS AOU San Martino-ISTUnit of Hematology and Clinical Immunology, University of PadovaHaematology and BMT Centre, Azienda Ospedaliero-Universitaria di ParmaHematology and Stem Cell Transplant Center, AORMN HospitalHematology Unit, Department of Medical Sciences and Public Health, University of CagliariInternal Medicine II, Hematology and Oncology, Friedrich-Schiller-University Medical CenterDepartment of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico IIDivision of Hematology, AUSL di PiacenzaAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di EmatologiaAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di EmatologiaHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoDepartment of Medicine, Section of Hematology, University of VeronaDivision of Hematology, Ospedale S. EugenioDivision of Hematology and BMT, Department of Medical Area, University of UdineDivision of Hematology, AOU Policlinico V. Emanuele, University of CataniaDepartment of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico IIDivision of Hematology, University of FerraraDepartment of Medicine, Section of Hematology, University of VeronaUnit of Hematology and Clinical Immunology, University of PadovaClinic of Hematology, Department of Internal Medicine (DiMI), IRCCS AOU San Martino-ISTHematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore PoliclinicoAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di EmatologiaAzienda Ospedaliero-Universitaria di Bologna, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S.Orsola-Malpighi, Dipartimento di Oncologia e di EmatologiaDivision of Cellular Biotechnologies and Hematology, University SapienzaDepartment of Medicine, Section of Hematology, University of Veronahttps://doi.org/10.1038/s41408-020-00392-1 |
| spellingShingle | Francesca Palandri Giuseppe Alberto Palumbo Elena Maria Elli Nicola Polverelli Giulia Benevolo Bruno Martino Elisabetta Abruzzese Mario Tiribelli Alessia Tieghi Roberto Latagliata Francesco Cavazzini Micaela Bergamaschi Gianni Binotto Monica Crugnola Alessandro Isidori Giovanni Caocci Florian Heidel Novella Pugliese Costanza Bosi Daniela Bartoletti Giuseppe Auteri Daniele Cattaneo Luigi Scaffidi Malgorzata Monica Trawinska Rossella Stella Fiorella Ciantia Fabrizio Pane Antonio Cuneo Mauro Krampera Gianpietro Semenzato Roberto Massimo Lemoli Alessandra Iurlo Nicola Vianelli Michele Cavo Massimo Breccia Massimiliano Bonifacio Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis Blood Cancer Journal |
| title | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_full | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_fullStr | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_full_unstemmed | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_short | Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis |
| title_sort | ruxolitinib discontinuation syndrome incidence risk factors and management in 251 patients with myelofibrosis |
| url | https://doi.org/10.1038/s41408-020-00392-1 |
| work_keys_str_mv | AT francescapalandri ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT giuseppealbertopalumbo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT elenamariaelli ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT nicolapolverelli ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT giuliabenevolo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT brunomartino ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT elisabettaabruzzese ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT mariotiribelli ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT alessiatieghi ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT robertolatagliata ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT francescocavazzini ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT micaelabergamaschi ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT giannibinotto ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT monicacrugnola ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT alessandroisidori ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT giovannicaocci ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT florianheidel ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT novellapugliese ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT costanzabosi ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT danielabartoletti ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT giuseppeauteri ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT danielecattaneo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT luigiscaffidi ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT malgorzatamonicatrawinska ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT rossellastella ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT fiorellaciantia ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT fabriziopane ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT antoniocuneo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT maurokrampera ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT gianpietrosemenzato ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT robertomassimolemoli ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT alessandraiurlo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT nicolavianelli ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT michelecavo ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT massimobreccia ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis AT massimilianobonifacio ruxolitinibdiscontinuationsyndromeincidenceriskfactorsandmanagementin251patientswithmyelofibrosis |